CannabisNewsBreaks

WednesdayJan 10, 2024 3:20 pm

CannabisNewsBreaks – Why Astrotech Corporation (NASDAQ: ASTC) Is ‘One to Watch’

Astrotech (NASDAQ: ASTC ) is an instrumentation company that designs, manufactures and commercializes solutions. These include mass spectrometry, process controls, chemical detectors and medical disease detection. The company is headquartered in Austin, Texas, and owns four subsidiaries: Astrotech Technologies Inc., 1st Detect Corp., AgLAB Inc., and BreathTech Corp. “Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (‘ECAC’) certification for the TRACER 1000(TM), the world’s first mass-spec Explosives Trace Detector (‘ETD’) used in airports worldwide,” a recent article reads. “Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a…

Continue Reading

TuesdayJan 09, 2024 1:19 pm

CannabisNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew something great was in the making,” said Branded Legacy CEO David Oswald. “It is a rare enough thing to find a company motivated primarily by the positive impact they can make on society. We are…

Continue Reading

TuesdayJan 09, 2024 12:14 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) Featured in Bell2Bell Podcast

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a global infrastructure and holding company in the cannabis industry, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Jose Gabriel Diaz, CEO of Software Effective Solutions, joined the program to provide an introduction to MedCana and its business model. “We are a U.S.-based holding company focused on developing infrastructure and cannabis companies around the world. Right now, the focus is primarily on markets outside of the U.S. that have already fully legalized pharmaceutical (and possibly some…

Continue Reading

FridayJan 05, 2024 1:20 pm

CannabisNewsBreaks – IBN, CannabisNewsWire Re-Engaged for NECANN’s 2024 Event Lineup

IBN, a multifaceted financial news and publishing company, today announced its expanded collaboration with NECANN, which specializes in orchestrating conventions that focus on the development and expansion of cannabis markets. Under the agreement, IBN’s CannabisNewsWire will continue to serve as the official newswire for the organization’s annual conference lineup. As part of the collaboration, IBN will amplify its support through its syndication network, providing comprehensive coverage for NECANN events. In collaboration with its network of 60+ online brands such as CannabisNewsWire and CannabisNewsWatch, IBN will deploy an extensive range of corporate-communications solutions to enhance visibility and recognition of conference participants…

Continue Reading

ThursdayJan 04, 2024 2:25 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive final results from its recently completed human Pilot Study #1 evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide available commercially in the branded product Rybelsus(R). According to the announcement, the study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet (“control”) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“DehydraTECH GLP-1”). In general, the DehydraTECH processing enabled improvements…

Continue Reading

TuesdayDec 26, 2023 3:45 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). “So far, Lexaria has received 37 granted patents globally, with many pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead to an increase in shareholder value as a recognized growing market leader,” a recent article reads. “‘Because of the applicability of DehydraTECH to many market sectors across the globe, we have taken the necessary…

Continue Reading

FridayDec 22, 2023 2:11 pm

CannabisNewsBreaks – BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) Closes US$1.5M Registered Direct Offering

BYND Cannasoft (NASDAQ: BCAN) (CSE: BYND), an Israeli-based integrated software and cannabis company, has announced the closing of the previously disclosed registered direct offering with an institutional investor of approximately $1.5 million common shares and investor warrants at a price of $0.52 per common unit. The company secured approximately $1.5 million in aggregate gross proceeds and expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital. The transaction closed on Dec. 21, 2023. Aegis Capital Corp. is acting as exclusive placement agent for the offering. Louis A. Brilleman, P.C.…

Continue Reading

ThursdayDec 21, 2023 4:59 pm

CannabisNewsBreaks – WEED Inc.’s (BUDZ) HEMP BioSciences Inc. Receives Full Suite of Industrial Hemp Licenses from State of Arizona

WEED (OTCQB: BUDZ) is a global cannabis and hemp bioresearch company based in the U.S. focused on the development and application of cannabis–derived compounds for the treatment of human and animal diseases. The company, together with its HEMP BioSciences Inc. (“HEMP”) division, today announced its intention to expand into consumer packaged goods utilizing its rare Landrace strains including Original Panama Red, Acapulco Gold, Red Bud Colombian and Santa Marta Gold. “HEMP has been issued all required licenses for Industrial HEMP; Growing, Nursery, Harvester, Transporter and Processor licenses under Title 3-Chapter 2-Article 4.1 of The Arizona Department of Agriculture,” said Nicole…

Continue Reading

WednesdayDec 20, 2023 10:32 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held on Dec. 19, 2023, all matters considered by shareholders were approved; agenda items were sent to shareholders in a notice of meeting and management information communication that was released on Oct. 27, 2023. In addition, shareholders approved the election of five directors, including Eric A. Adams, Janet Grove, Andrew Hull, Nicole Lemerond and Bryan Baldasare; directors will hold their…

Continue Reading

FridayDec 15, 2023 3:50 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting New and More Lucrative Global Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for the treatment of diabetes and weight loss. “The move could help Lexaria carve out an important market share for an industry that is projected to bring in between $150 billion and $200 billion a year. Given the positive results the company has achieved so far in its diabetes and hypertension clinical studies, Lexaria is optimistic that its foray into GLP-1 drugs will yield positive results and open up its technology to…

Continue Reading